SOURCE: NeuroInvestment

September 07, 2005 09:00 ET

Insomnia Programs Reviewed by NeuroInvestment

CARDIFF, CA -- (MARKET WIRE) -- September 7, 2005 -- NI Research today announced the release of the September issue of NeuroInvestment, which reviews and evaluates the coming generation of insomnia drugs. Insomnia is one of the largest untreated diagnostic categories, with only a small percentage of those suffering from insomnia utilizing any of the pharmaceutical options available to date, due largely to concerns regarding dependency and tolerance. This has changed with the impressive advent of Sepracor's Lunesta, the first medication for insomnia to be approved for longterm use. Competition for the insomnia market will see a seismic surge in intensity when Pfizer and Neurocrine Bioscience's (NASDAQ: NBIX) indiplon is approved towards mid-2006, with the Pfizer/Neurocrine entry marking the beginning of what will be one of the epic marketing battles in the history of pharmaceuticals. Besides indiplon and Lunesta, programs of note include Takeda's Rozerem, will be of interest due to its melatonin receptor based mechanism, although its prospects are solely as a sleep-induction aid. Sanofi-Aventis is attempting to give its Ambien franchise new life with a controlled release version, while Merck/Lundbeck and Somaxon have insomnia drugs in advanced clinical trials. The two winners in this contest will have sales of more than $1 billion annually, with first place worth in excess of $2 billion per year in sales.

Recent issues of NI have reviewed epilepsy, spinal cord injury, ADHD, and schizophrenia. Forthcoming issues will review programs in neurogenesis and Alzheimer's.

NeuroInvestment Subscription Rates:

Pharmaceutical: 3-month trial $350, 1 year $1250, 2 years $2280

Individual Investor: 3-month trial $150, 1 year $450, 2 years $800

Outside the US/Canada add $40 per year for hardcopy airmail. For combined hardcopy and email delivery, add $150 per year ($50 for individuals).

Information about NeuroInvestment's Institutional Edition is available on request.

NI Research is the leading publisher of independent research regarding the CNS therapeutics area. NI has just marked its tenth year, having published NeuroInvestment since 1995. NI Research also publishes the annual Private CNS Company Review, whose 2005 edition has recently been released; and provides product licensing consultation and custom research for large and small pharmaceutical firms.

Contact Information